Advertisement for orthosearch.org.uk
Results 1 - 4 of 4
Results per page:
Orthopaedic Proceedings
Vol. 94-B, Issue SUPP_XXXVII | Pages 424 - 424
1 Sep 2012
Antonarakos P Christodoulou A Givissis P Katranitsa L Simeonidis P Boutsiadis A
Full Access

AIM. Retrospective study comparing the effectiveness of preoperative autologous blood donation versus intra-operative blood saver systems in minimizing the need for allogeneic blood transfusion in scoliosis surgery. MATERIALS – METHODS. Between 2003–2009, 37 of the patients (4–33, mean age 20y) who underwent scoliosis surgery, were divided in two groups. The first group (20 patients, mean age 18.7y) underwent autologous blood predonation, prerequisities were body weight over 50 kgr and Hgb above 11 mg/dl. The second group (17 patients, mean age 21.5y) consisted of patients who did not meet the above prerequisities and blood saver was used intra-operatively. Duration of surgery and perioperative Haemoglobulin (Hgb) levels were recorded in both groups. RESULTS. In group A an average of 4 autologous blood units per patient were predonated (3–5 units/patient) and the mean transfusion rate was 3.4 autologous blood units/patient. Only one patient was transfused with one allogeneic blood unit while of the 81 predeposited autologous blood units 15 were wasted (18.5%). In Group B intra-operative autotransfusion systems salvaged 302.9 ml/patient (150–500 ml/patient) while the mean transfusion rate was 2.1 allogeneic blood units/patient. CONCLUSIONS. The use of intra-operative autotransfusion systems seems to reduce the need for allogeneic blood transfusion when compared with preoperative autologous blood donation. However, the lower preoperative Hgb in Group B have to be taken under consideration. Further studies need to prove the effectiveness of these methods so that perioperative blood management minimizes the need for allogeneic blood transfusion in scoliosis surgery


Orthopaedic Proceedings
Vol. 94-B, Issue SUPP_XXXVII | Pages 432 - 432
1 Sep 2012
Zacharopoulos A Papanikolaou S Vezirgiannis I Kechagias V Cristodoulopoulos C Papadopoulos C Besikos I Xenos G Moscachlaidis S
Full Access

Purpose. To evaluate the long term results of the use of a postoperative autologous blood reinfusion system in total knee arthroplasty. Material and method. In a prospective study, 176 patients who underwent unilateral total knee replacement, during the period 2004–2008, were evaluated (study group or group A). In all these patients a reinfusion system of unwashed blood salvaged was applied, while supplementary homologous blood transfusion was performed when required. The admission of banked blood transfusion determined by haemoglobin value (<9mg/dL) and/or clinical signs (blood pressure, pulses, etc). The value of haemoglobin, haematocrite and platelets recorded preoperatively and the 1st, 5th and 15th day after operation. Results were compared with the material of our previous prospective randomized controlled study (control groups B and C), where in 60 patients, between the years 2002–2004, the effectiveness of postoperative autologous blood reinfusion had been proved. Results. 19 patients of group A required postoperatively 23 units of homologous blood (total study group requirements23 blood units or 0.13 units per patient) while in group B required 1.5 units/patient and in group C 0.3 units/patient. In the study group the total homologous blood requirements reduced by 91% compared with group B (patients without autotransfusion system applied) and by 47% compared with group C (patients with autotransfusion system applied). There was no statistically significant difference in the postoperative values of Hb and Ht between the groups. None of the patients developed any adverse reactions after reinfusion. The cost of blood management was reduced in study group by 76%. Conclusions. The use of an autotransfusion system postoperatively minimizes practically the demands for homologous banked blood transfusion in total knee arthroplasty


The Bone & Joint Journal
Vol. 104-B, Issue 11 | Pages 1256 - 1265
1 Nov 2022
Keene DJ Alsousou J Harrison P O’Connor HM Wagland S Dutton SJ Hulley P Lamb SE Willett K

Aims

To determine whether platelet-rich plasma (PRP) injection improves outcomes two years after acute Achilles tendon rupture.

Methods

A randomized multicentre two-arm parallel-group, participant- and assessor-blinded superiority trial was undertaken. Recruitment commenced on 28 July 2015 and two-year follow-up was completed in 21 October 2019. Participants were 230 adults aged 18 years and over, with acute Achilles tendon rupture managed with non-surgical treatment from 19 UK hospitals. Exclusions were insertion or musculotendinous junction injuries, major leg injury or deformity, diabetes, platelet or haematological disorder, medication with systemic corticosteroids, anticoagulation therapy treatment, and other contraindicating conditions. Participants were randomized via a central online system 1:1 to PRP or placebo injection. The main outcome measure was Achilles Tendon Rupture Score (ATRS) at two years via postal questionnaire. Other outcomes were pain, recovery goal attainment, and quality of life. Analysis was by intention-to-treat.


Orthopaedic Proceedings
Vol. 94-B, Issue SUPP_XXXVII | Pages 212 - 212
1 Sep 2012
Monto R
Full Access

Chronic plantar fasciitis is a common but sometimes difficult condition to successfully treat. Platelet rich plasma (PRP), a concentrated bioactive component of autologous blood that is rich in cytokines and other growth factors, was compared with cortisone injection in the treatment of severe cases of plantar fasciitis resistant to traditional non-operative paradigms. Thirty-six patients (16 males 20 females) were prospectively block-randomized into two study groups. All patients had pre-treatment MRI and ultrasound studies consistent with plantar fasciitis. The first group was treated with a single ultrasound guided injection of 40 mg Depo-Medrol at the injury site and the second group was treated with a single ultrasound guided injection of un-buffered autologous PRP at the injury site. The cortisone group had an average age of 59 (24–74) and had failed 4 months (3–24) of standard non-operative management (rest, heel lifts, PT, NSAIDS, cam walker immobilization, night splinting, local modalities) and had pre-treatment AOFAS scores of 52 (24–60). The PRP group had an average age of 51 (21–67) and had failed 5 months (3–26) of standard non-operative management (rest, heel lifts, PT, NSAIDS, cam walker immobilization, night splinting, local modalities) and had pre-treatment AOFAS scores of 37 (30–56). All patients were then immobilized fully weight bearing in a cam walker for 2 weeks, started on eccentric home exercises and then allowed to return to normal activities as tolerated and without support. Post-treatment AOFAS scores in the cortisone initially improved to 81(60–90) at 3 months but decreased to 74 (56–85) at 6 months. Post-treatment AOFAS scores in the PRP group improved to 95 (84–90) at 3 months and remained excellent at 94 (87–100) at 6 months follow-up. This study suggests that platelet rich plasma injection is more effective and durable than cortisone injection for the treatment of severe chronic plantar fasciitis refractory to traditional non-operative management